newsfilter
← Latest News
GlobeNewswire·

Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027